Moleculin is in the process of updating its iPSP to incorporate FDA’s recommendations and intends to submit the revised plan to FDA later this quarter. Moleculin expects to initiate pediatric clinical ...

"The POSITANO study shows that CAM2029 significantly reduces liver and liver cyst volume compared to placebo while showing improvements in symptoms as assessed by relevant patient ...

Introduction Over the past few years, the European Union has been actively working to overhaul its pharmaceutical legislative framework to better address unmet medical needs, such as those ...

Early intervention in high-risk smoldering myeloma with lenalidomide delays progression by up to 7 years and achieves ...

Shares in Neuren Pharmaceuticals advanced in morning trade after Macquarie initiated coverage of the biopharmaceutical company with an 'outperform' rating.

Revenues increased 9% in Q4 2025 compared to Q4 2024, and 12% in FY 2025 compared to FY 2024Net loss improved 27% in Q4 2025 compared to Q4 2024, and 29% in FY 2025 compared to FY 2024EBITDA loss ...

The Patented Medicine Prices Review Board (PMPRB) published the 9th edition of its annual Meds Entry Watch report today. Like last year, the analysis finds that the number of new medicines launched in ...

The Patented Medicine Prices Review Board (PMPRB) published the 9th edition of its annual Meds Entry Watch report today. Like last year, the analysis ...

IT's an incontrovertible fact that, as the political scientist John Mearsheimer, co-author of the landmark book, 'The Israel ...

The biotech industry faces a mix of longstanding and novel political challenges amid President Donald Trump’s second term.

The global Biosimilars Market, valued at US$32.75 billion in 2024 stood at US$35.04 billion in 2025 and is projected to advance at a resilient ...